Builders #25 w/ Marion Dorsch & Jared Rutter - Co-Founder & CSO / Co-Founder @ Atavistik Bio | BIOS

Guests: Marion Dorsch & Jared Rutter, Co-Founders @ Atavistik Bio

Marion Dorsch: President & CSO @ Atavistik Bio

Marion Dorsch brings over 20 years of drug discovery experience in oncology, inflammation and rare genetic diseases to Atavistik Bio. She is an accomplished scientist and senior executive with a proven track record of discovering and advancing innovative therapies to patients. Most recently, Marion served as Chief Scientific Officer at Blueprint Medicines, where she led the Discovery and Translational Medicine teams and oversaw the progression of a strong portfolio of precision medicines. She joined Blueprint Medicines from Agios where she was the Vice President of Biology and responsible for novel target validation, drug discovery, and biomarker strategy across Agios’ portfolio. Prior to Agios, Marion was Director of Cancer Biology at Sanofi Oncology, Group leader in Oncology at the Novartis and part of the Inflammation group at Millennium Pharmaceuticals. During her tenure in biotech and pharma, Marion has made major contributions to the discovery and development of 6 FDA-approved precision medicines: Odomzo (SMO), Kisqali (CDK4/6), Idhifa (IDH2), Tibsovo (IDH1), Ayvakit (KIT/PDGFR) and Gavreto (RET).

Marion received her PhD in Biology from the Free University of Berlin, Germany and was a postdoctoral fellow in the laboratory of Dr. Stephen Goff at Columbia University in New York.

&

Jared Rutter, Co-Founder of Atavistik

Dr. Jared Rutter is a Distinguished Professor of Biochemistry and holds the Dee Glen and Ida Smith Endowed Chair for Cancer Research at the University of Utah where he has been on the faculty since 2003. He has been an Investigator of the Howard Hughes Medical Institute since 2015. Dr. Rutter performed undergraduate studies at Brigham Young University and received his PhD from the University of Texas Southwestern Medical Center in 2001, working with Dr. Steve McKnight. After receiving his PhD, he spent 18 months as the Sara and Frank McKnight Independent Fellow of Biochemistry before joining the faculty at the University of Utah.

The Rutter laboratory has characterized the PAS kinase protein as an important factor in states of metabolic dysregulation—including obesity and diabetes. More recently, the Rutter laboratory and collaborators have identified the functions of several previously uncharacterized mitochondrial proteins, including the discovery of the long-sought mitochondrial pyruvate carrier. This knowledge has now enabled for the first time the demonstration that this critical metabolic step is impaired in a variety of human diseases, including cancer and cardiovascular disease. In addition, the Rutter lab is taking multiple approaches to understand how metabolic state influences cell fate and cell behavior decisions.

Dr. Rutter is actively involved in translating academic discoveries into therapies for patients. This has included founding and/or serving as a consultant or member of the advisory board of several companies. Dr. Rutter also serves as co-Director of the Diabetes and Metabolism Center at the University of Utah and co-Leader of the Nuclear Control of Cell Growth and Differentiation at Huntsman Cancer Institute.

Host(s): Chris Ghadban
_______________________

Join BIOS Community 🎉
Become a member, continue the conversation, connect with like-minded Life Science innovators, access exclusive resources, & invite-only events…

For More Interesting Content 💭

_______________________

BIOS: Nucleus of Life Science Innovation 🚀

Alix Ventures: Driving Patient Impact - Supporting Early Stage Startups Engineering Biology to Create Radical Advances in Human Health🌟